Tuesday, June 19, 2018 10:36:53 PM
ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office ("USPTO") has issued an...
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com
SOURCE ReShape Lifesciences Inc.
SAN CLEMENTE, Calif., June 19, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office ("USPTO") has issued an Issue Notification for U.S. Patent Number 10010441 entitled "Gastric Restriction Device for Treating Obesity," which covers a patent application regarding the Company's Gastric Vest System (the "ReShape VestTM"). Barring any unforeseen circumstances, this patent will be valid until December 5, 2028.
The ReShape Vest, a new investigational medical device for weight loss in obese patients, wraps around the stomach and is designed to emulate conventional bariatric surgery without permanent anatomical changes. The ReShape Vest can be implanted in a minimally-invasive procedure with a goal to control weight gain and obesity. Patent No. 10010441 has broad claims directed to a skirt or a wrap that is shaped to form-fit and be securely fastened around the stomach of a patient to prevent expansion of the stomach.
"The ReShape Vest is a novel and ground-breaking advancement in the obesity space. This patent allowance represents a key milestone towards our launch of this revolutionary product for patients suffering from obesity and our physician customers who treat these patients" said Dan Gladney, Chairman and Chief Executive Officer of ReShape Lifesciences™. "The patent will provide intellectual property coverage to help ReShape Lifesciences secure a proprietary position in the market for decades as we move toward commercialization of this life- changing technology."
About ReShape Lifesciences Inc.
ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved ReShape Balloon™ System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to take up room in the stomach to help people with a 30-40 kg/m2 Body Mass Index (BMI) and at least one co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an FDA-approved pacemaker-like device called the ReShape vBloc System, is designed to help patients with a 40-45 kg/m2, or a 35-39.9 kg/m2 BMI and at least one co-morbidity feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release include statements regarding our ability to commercialize the ReShape Vest and that the patent will provide intellectual property coverage to help us secure a proprietary position in the market for decades. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisitions of ReShape Medical, Inc. and BarioSurg, Inc.; risks related to the U.S. Food and Drug Administration's announcement to alert health care providers of unanticipated deaths involving the ReShape Balloon; our proposed ReShape Vest product may not be successfully developed and commercialized; our ability to continue as a going concern if we are unsuccessful in our pursuit of various funding options; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our vBloc system or ReShape Balloon; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed April 2, 2018. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
ReShape Lifesciences Inc. logo
Cision View original content with multimedia:www.prnewswire.com/news-releases/reshape-lifesciences-receives-uspto-issue-notification-for-patent-covering-its-reshape-vest-300668239.html
Recent RSLS News
- ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System • GlobeNewswire Inc. • 03/28/2024 12:31:00 PM
- ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 03/04/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:19:43 PM
- ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 02/22/2024 01:31:00 PM
- ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 01/24/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:38:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 11:11:06 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/05/2024 09:14:25 PM
- ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives • GlobeNewswire Inc. • 12/20/2023 01:31:00 PM
- ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:05:16 PM
- ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds • GlobeNewswire Inc. • 11/21/2023 01:06:14 PM
- ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan • GlobeNewswire Inc. • 11/08/2023 09:05:00 PM
- ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update • GlobeNewswire Inc. • 11/06/2023 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 08:42:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:13 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 10/03/2023 01:23:13 PM
- ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering • GlobeNewswire Inc. • 09/29/2023 04:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/27/2023 09:30:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:02:52 PM
- ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI • GlobeNewswire Inc. • 09/22/2023 12:31:00 PM
- ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System • GlobeNewswire Inc. • 09/21/2023 12:31:00 PM
- ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System • GlobeNewswire Inc. • 09/19/2023 12:31:00 PM
- ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device • GlobeNewswire Inc. • 09/14/2023 12:31:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM